Compensation of Research-Related Injuries in the European Union

in European Journal of Health Law
Restricted Access
Get Access to Full Text
Rent on DeepDyve

Have an Access Token?



Enter your access token to activate and access content online.

Please login and go to your personal user account to enter your access token.



Help

Have Institutional Access?



Access content through your institution. Any other coaching guidance?



Connect

The planned reform of the Clinical Trials Directive has re-opened the debate over how to implement and interpret research-related injuries regulation. In the European Union (eu), clinical trials are currently regulated by Directive 2001/20/ec, which establishes the provision of mandatory insurance before clinical trials commence but is silent on the system of liability. The proposed new Regulation will impact biomedical research assurance in all eu Member States because it points to insurance costs as being one of the causes of the fall in the number of clinical trials carried out in the eu. Despite the adoption of a risk-balance approach, the proposed new Regulation does not include a no-fault compensation system to protect subjects participating in clinical trials. An adequate protection of the rights and wellbeing of trial subjects would require not only mandatory insurance for clinical trials but also a no-fault compensation system. The new regulation should include a general clause requiring mandatory insurance and establishing liability insurance based on no-fault compensation; an exception clause, enabling the performance of clinical trials without insurance in the case of low-risk interventions or non-commercial clinical trials; and an exclusion clause, excluding compensation when there is no causal connection between injuries and clinical trial.

Compensation of Research-Related Injuries in the European Union

in European Journal of Health Law

Sections

References

1

E.R. Pike“Recovering from Research: A No-Fault Proposal to Compensate Injured Research Participants”American Journal of Law & Medicine 38 (2012) 7-62at p. 11.

6

M. Czarkowski“The Protection of Patients’ Rights in Clinical Trials”Science and Engineering Ethics 12 (2006) 131-138at pp. 134-135.

9

C. Trouet M. Gobert and M. PodoorClinical Trials in Belgium. The Belgian Implementation of the European Clinical Trials Directives (Antwerp: Intersentia2007) at p. 40 available online: www.ejustice.just.fgov.be.

21

A. Rid and D. Wendler“A Framework for Risk-Benefit Evaluations in Biomedical Research”Kennedy Institute of Ethics Journal 21(2) (2011) 141-179.

22

M. Hartmann and F. Hartmann-Vareilles“Concepts for the Risk-Based Regulation of Clinical Research on Medicines and Medical Devices”Drug Information Journal 46(5) (2012) 545-554 at p. 547.

23

S. Gainotti and C. Petrini“Insurance Policies for Clinical Trials in the United States and in Some European Countries”Journal of Clinical Research and Bioethics1(1) (2010) at p. 2.

24

R.J. Levine“Clarifying the Concepts of Research Ethics”The Hastings Center Report 9(3) (1979) 21-26 at p. 22.

25

F.G. Miller and H. Brody“A Critique of Clinical Equipoise. Therapeutic Misconception in the Ethics of Clinical Trials”The Hastings Center Report 33(3) (2003) 19-28 at p. 20.

26

E.H. Morreim“Medical Research Litigation and Malpractice Tort Doctrines: Courts on a Learning Curve”Houston Journal of Health Law and Policy 4 (2003) 1-86at p. 16.

27

R.L. Jansson“Researcher Liability for Negligence in Human Subject Research: Informed Consent and Researcher Malpractice Actions”Washington Law Review 78 (2003) 229-263at pp. 236-237.

28

J. Childress“Compensating Injured Research Subjects: I. The moral argument”The Hastings Center Report 6 (1976) 21-27at p. 21.

32

L. Meltzer Henry“Moral Gridlock: Conceptual Barriers to No-Fault Compensation for Injured Research Subjects”The Journal of Law Medicine & Ethics 41 (2013) 411-423at p. 417.

34

C. Havighurst“Compensating Persons Injured in Human Experimentation”Science 169 (1970) 153-157at p. 153.

40

P.R. Ferguson“Clinical Trials and Healthy Volunteers”Medical Law Review 16 (2008) 23-51at p. 23; Expert Scientific Group on Phase One Clinical Trials Final Report (Norwich: The Stationery Office 2006) at pp. 30-35; Royal Statistical Society Report of the Working Group on Statistical Issues in First-in-Man Studies (London 2007) at pp. 7-9.

42

S. Lierman“European Product Safety, Liability and Single-Use Devices in a Medical Context”European Journal of Health Law 8 (2001) 207-224at p. 217.

43

R.J. Levine“Uncertainty in Clinical Research”Law Medicine & Health Care 16 (1988) 174-182at p. 174.

47

D.B. Resnik“Liability for Institutional Review Boards. From Regulation to Litigation”Journal of Legal Medicine 25 (2004) 131-184at p. 141.

51

B.A. Noah“Bioethical Malpractice: Risk and Responsability in Human Research”Journal of Health Care Law and Policy 7(2) (2004) 175-241 at p. 181.

57

D.B. Resnik“Compensation for Research-Related Injuries. Ethical and Legal Issues”Journal of Legal Medicine 27 (2006) 263-287at p. 266.

58

R. Steinbrook“Compensation for Injured Research Subjects”New England Journal of Medicine 354 (2006) 1871-1873at p. 1871.

60

L.D. Scott“Research-Related Injury: Problems and Solutions”The Journal of Law Medicine & Ethics 31 (2003) 419-428at p. 423.

61

R. MacklinDouble Standards in Medical Research in Developing Countries (Cambridge: Cambridge University Press2004).

64

B.R. Adams and M. Shea-Stonum“Toward a Theory of Control of Medical Experimentation with Human Subjects: The Role of Compensation”Case Western Reserve Law Review 25 (1974) 604-648at p. 612.

Index Card

Content Metrics

Content Metrics

All Time Past Year Past 30 Days
Abstract Views 12 12 2
Full Text Views 15 15 15
PDF Downloads 2 2 2
EPUB Downloads 0 0 0